Results 31 to 40 of about 424,438 (249)

Degradation mechanism of the von Willebrand factor A2 domain by nattokinase

FEBS Letters, EarlyView.
Nattokinase, a natto‐derived protease, exhibits potent antithrombotic effects. This study demonstrates that nattokinase directly cleaves the von Willebrand factor (vWF) A2 domain in vitro. Unlike the native regulator ADAMTS13, nattokinase degrades folded vWF independently of shear stress.
Ryuichi Hyakumoto, Masatomo So, Ayako Furukawa, Kenji Sugase   +3 more
wiley   +1 more source

Consórcio de medicamentos no Paraná: análise de cobertura e custos A drug consortium in Paraná: analysis of coverage and costs

Revista de Administração Pública, 2007
A redução de custos na compra de medicamentos é preocupação constante dos administradores públicos. Este artigo analisa a cobertura e custos do Consórcio Paraná Saúde (CPS), constituído para aquisição de medicamentos para prefeituras do Paraná.
Alide Marina Biehl Ferraes, Luiz Cordoni Junior   +1 more
doaj   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Biologics vs. small molecules: Drug costs and patient access

Medicine in Drug Discovery, 2021
Significant advances in drug research and development are herein reviewed first to set the background for a critical consideration of the economic sustainability of biologics and small molecules, why biologic drugs are more expensive, and how drug cost ...
Favour Danladi Makurvet
doaj   +1 more source

Pre‐analytical optimization of cell‐free DNA and extracellular vesicle‐derived DNA for mutation detection in liquid biopsies

Molecular Oncology, EarlyView.
Pre‐analytical handling critically determines liquid biopsy performance. This study defines practical best‐practice conditions for cell‐free DNA (cfDNA) and extracellular vesicle–derived DNA (evDNA), showing how processing time, storage conditions, tube type, and plasma input volume affect DNA integrity and mutation detection.
Jonas Dohmen, Lucrezia De Santis, Bret M. Stephens, Vincent Bernard, Jörg C. Kalff, Lara Braun, Phillipp Leyendecker, Johannes Röttgen, Daniel Weissinger, Anirban Maitra, Paola A. Guerrero, Alexander Semaan   +11 more
wiley   +1 more source

Referral Burden and Cost of Outpatient Care of Patients Covered by the Rural Insurance Fund before and after the Implementation of Electronic Referral System in Golestan Province

Rāhburdhā-yi Mudīriyyat dar Niẓām-i Salāmat, 2021
Background: Part of the major health costs is related to outpatient care. Since the costs of diagnosis and treatment are increasing rapidly and increasingly, this study was conducted to determine the referral burden and cost of outpatient care of ...
Anis Abbasi, Mohammad Javad Kabir, Fatemeh Kavian Telouri, Alireza Heidari, Zahra Khatirnamani, Narges Rafiei, Anahita Keshavarzi   +6 more
doaj  

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

Molecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, Iris te Paske, Vanja de Weerd, Corine M. Beaufort, Hans M. Westgeest, Jens Voortman, Maureen J. B. Aarts, Maud Rijnders, Astrid A. M. van der Veldt, Ronald de Wit, Niven Mehra, Saskia M. Wilting, Debbie G. J. Robbrecht   +14 more
wiley   +1 more source

Socioeconomic and Cost Analysis of Off‐Label Nebulized Ciprofloxacin‐Dexamethasone Use Following Airway Surgery

OTO Open
Objective Nebulized ciprofloxacin‐dexamethasone (CPD) is an adjuvant, off‐label treatment used to optimize healing after airway surgery, but there is limited data regarding its accessibility.
Abbey L. Landini, Cyrus W. Abrahamson, Jonathan P. Kuriakose, Jasmine Stewart, James A. Burns, Andrew P. Stein   +5 more
doaj   +1 more source

Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations

Cancer Medicine, 2019
Background The cost of new anticancer drugs is rising. We aimed to assess the clinical benefit and price of anti‐cancer drugs approved by the US Food and Drug Administration (FDA) for advanced gastrointestinal cancers. Methods Drugs approved between 2006
Di Maria Jiang, Kelvin K. W. Chan, Raymond W. Jang, Christopher Booth, Geoffrey Liu, Eitan Amir, Robert Mason, Louis Everest, Elena Elimova   +8 more
doaj   +1 more source

The costs of introducing artemisinin-based combination therapy: evidence from district-wide implementation in rural Tanzania

Malaria Journal, 2008
Background The development of antimalarial drug resistance has led to increasing calls for the introduction of artemisinin-based combination therapy (ACT).
Abdulla Salim, Mchomvu Naiman, Munkondya John S, Mulligan Jo, Kachur S Patrick, Goodman Catherine A, Njau Joseph D, Bloland Peter, Mills Anne   +8 more
doaj   +1 more source